赵娟;王洪涛;陈岩;杨远荣;

• 1:荆州市中心医院药学部

摘要(Abstract)：

抑郁和焦虑是帕金森病(PD)常见的非运动症状,对患者的情绪和生活质量产生极大的负面影响。目前针对PD抑郁焦虑的治疗还缺乏足够的循证医学证据。本文对近年来的有关PD抑郁焦虑治疗药物的文献进行综述,为临床用药选择提供依据,以便临床医师及时有效地对PD抑郁焦虑症状进行干预。

关键词(KeyWords)： 帕金森病;抑郁;焦虑;药物治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 赵娟;王洪涛;陈岩;杨远荣;

Email:

DOI: 10.14053/j.cnki.ppcr.202103020

参考文献(References)：

• [1] Statistics.New York,NY:Parkinson′s Foundation[EB/OL].[2019-1-31].https://www.parkinson.org/Understanding-Parkinsons/Statistics.
• [2] Weintraub D,Comella CL,Horn S.Parkinson′s disease-Part 3:neuropsychiatric symptoms[J].Am J Manag Care,2008,14(2 Suppl):S59-69.
• [3] Tu XJ,Hwang WJ,Ma HI,et al.Determinants of generic and specific health-related quality of life in patients with Parkinson′s disease[J].PLoS One,2017,12(6):e0178896.
• [4] Pellicano C,Benincasa D,Pisani V,et al.Prodromal non-motor symptoms of Parkinson′s disease[J].Neuropsychiatr Dis Treat,2007,3(1):145-152.
• [5] de la Riva P,Smith K,Xie SX,et al.Course of psychiatric symptoms and global cognition in early Parkinson′s disease[J].Neurology,2014,83(12):1096-1103.
• [6] Raskind MA.Diagnosis and treatment of depression comorbid with neurologic disorders[J].Am J Med,2008,121(11 Suppl 2):S28-S37.
• [7] Zhu K,van Hilten JJ,Marinus J.Associated and predictive factors of depressive symptoms in patients with Parkinson′s disease[J].Neurol,2016,263:1215-1225.
• [8] Larsen JP,Dalen I,Pedersen KF,et al.The natural history of depressive symptoms in patients with incident Parkinson′s disease:a prospective cohort study[J].J Neurol,2017,264(12):2401-2408.
• [9] Wee N,Kandiah N,Acharyya S,et al.Depression and anxiety are comorbid but dissociable in mild Parkinson′s disease:a prospective,longitudinal study of patterns and predictors[J].Parkinsonism RelDisord,2016,23:50-56.
• [10] Dissanayaka NN,Sellbach A,Matheson S,et al.Anxiety disorders in Parkinson′s disease:prevalence and risk factors[J].Mov Disord,2010,25(7):838-845.
• [11] Leentjens AF,Dujardin K,Marsh L,et al.Anxiety and motor fluctuations in Parkinson′s disease:a cross-sectional observational study[J].Parkinsonism Relat Disord,2012,18(10):1084-1088.
• [12] Hanganu A,Bruneau MA,Degroot C,et al.Depressive symptoms in Parkinson′s disease correlate with cortical atrophy over time[J].Brain Cogn,2017,111:127-133.
• [13] Huang P,Xuan M,Gu Q,et al.Abnormal amygdala function in Parkinson′s disease patients and its relationship to depression[J].J Affective Disord,2015,183:263-268.
• [14] Anders S,Sack B,Pohl A,et al.Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele[J].Brain,2012,135(Pt 4):1128-1140.
• [15] Prediger RD,Matheus FC,Schwarzbold ML,et al.Anxiety in Parkinson′s disease:a critical review of experimental and clinical studies[J].Neuropharmacology,2012,62(1):115-124.
• [16] Richard IH,McDermott MP,Kurlan R,et al.A randomized,double-blind,placebo-controlled trial of antidepressants in Parkinson disease[J].Neurology,2012,78(16):1229-1236.
• [17] Chen JJ,Marsh L.Depression in Parkinson′s disease:identification and management[J].Pharmacotherapy,2013,33(9):972-983.
• [18] Bonuccelli U,Meco G,Fabbrini G,et al.A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson′s disease[J].Expert Opin Pharmacother,2012,13(16):2269-2280.
• [19] Nishijima H,Ueno T,Kon T,et al.Effects of duloxetine on motor and mood symptoms in Parkinson′s disease:an open-label clinical experience[J].J Neurol Sci,2017,375:186-189.
• [20] Troeung L,Egan SJ,Gasson N.A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson′s disease[J].PLoS One,2013,8(11):e79510.
• [21] Rocha FL,Murad MG,Stumpf BP,et al.Antidepressants for depression in Parkinson′s disease:systemic review and meta-analysis[J].Psychopharmacol,2013,27:417-423.
• [22] Leentjens AF.The role of dopamine agonists in the treatment of depression in patients with Parkinson′s disease:a systematic review[J].Drugs,2011,71(3):273-286.
• [23] Joutsa J,Martikainen K,Vahlberg T,et al.Impulse control disorders and depression in Finnish patients with Parkinson′s disease[J].Parkinsonism Relat Disord,2012,18(2):155-160.
• [24] Korchounov A,Winter Y,R?ssy W.Combined beneficial effect of rasagiline on motor function and depression in de novo PD[J].Clin Neuropharmacol,2012,35(3):121-124.
• [25] Shulman KI,Herrmann N,Walker SE.Current place of monoamine oxidase inhibitors in the treatment of depression[J].CNS Drugs,2013,27(10):789-797.
• [26] Cattaneo C,Müller T,Bonizzoni E,et al.Long-term effects of safinamide on mood fluctuations in Parkinson′s disease[J].J Parkinsons Dis,2017,7(4):629-634.
• [27] Bianchi M,Riboldazzi G,Mauri M,et al.Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson′s disease[J].Neurol Sci,2019,40(2):275-279.
• [28] Za?uska M,Dyduch A.Bupropion in the treatment of depression in Parkinson′s disease[J].Int Psychogeriatr,2011,23(2):325-327.
• [29] Sawada H,Umemura A,Kohsaka M,et al.Pharmacological interventions for anxiety in Parkinson′s disease sufferers[J].Expert Opin Pharmacother,2018,19(10):1071-1076.
• [30] Wu PL,Lee M,Huang TT.Effectiveness of physical activity on patients with depression and Parkinson′s disease:a systematic review[J].PLoS One,2017,12(7):e0181515.